| Dr Elma O Sia, MD | |
|
4410 Regent St, Madison, WI 53705-4901 | |
| (608) 233-9746 | |
| Not Available |
| Full Name | Dr Elma O Sia |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 4410 Regent St, Madison, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003878893 | NPI | - | NPPES |
| 31435000 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 29304-020 (Wisconsin) | Primary |
| Entity Name | Associated Physicians, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861412785 PECOS PAC ID: 7719953306 Enrollment ID: O20040903001206 |
News Archive
Archbishop Joseph E. Kurtz of Louisville, Kentucky, president of the U.S. Conference of Catholic Bishops (USCCB) welcomed the move by the U.S. Supreme Court, January 24, to extend an injunction granted by Justice Sonia Sotomayor, December 31, exempting the Little Sisters of the Poor and others in their lawsuit from the Department of Health and Human Services' contraception mandate while their appeal is pending.
Ironwood Pharmaceuticals, Inc. today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood's Class A common stock. With the completion of the IPO and the exercise of the over-allotment option, Ironwood has approximately 97.4 million shares of common stock outstanding (approximately 19.2 million shares of Class A common stock and 78.2 million shares of Class B common stock).
Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.
The National Center for Research Resources (NCRR), a part of the National Institutes of Health (NIH), announced today it will provide up to an estimated $11 million over the next five years to create two new Biomedical Technology Research Centers (BTRCs) that will provide researchers nationwide with access to specialized research tools, training and state-of-the-art equipment.
The MitoCanada Foundation has announced a national research venture focused on improving the early detection and treatment of mitochondrial disease in Canada.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Elma O Sia, MD 4410 Regent St, Madison, WI 53705-4901 Ph: (608) 233-9746 | Dr Elma O Sia, MD 4410 Regent St, Madison, WI 53705-4901 Ph: (608) 233-9746 |
News Archive
Archbishop Joseph E. Kurtz of Louisville, Kentucky, president of the U.S. Conference of Catholic Bishops (USCCB) welcomed the move by the U.S. Supreme Court, January 24, to extend an injunction granted by Justice Sonia Sotomayor, December 31, exempting the Little Sisters of the Poor and others in their lawsuit from the Department of Health and Human Services' contraception mandate while their appeal is pending.
Ironwood Pharmaceuticals, Inc. today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood's Class A common stock. With the completion of the IPO and the exercise of the over-allotment option, Ironwood has approximately 97.4 million shares of common stock outstanding (approximately 19.2 million shares of Class A common stock and 78.2 million shares of Class B common stock).
Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.
The National Center for Research Resources (NCRR), a part of the National Institutes of Health (NIH), announced today it will provide up to an estimated $11 million over the next five years to create two new Biomedical Technology Research Centers (BTRCs) that will provide researchers nationwide with access to specialized research tools, training and state-of-the-art equipment.
The MitoCanada Foundation has announced a national research venture focused on improving the early detection and treatment of mitochondrial disease in Canada.
› Verified 7 days ago
Dr. Emily Ann Forster, MD Pediatrics Medicare: Medicare Enrolled Practice Location: Uw Hospitals & Clinics 600 Highland Ave, Madison, WI 53792 Phone: 608-263-6400 | |
Dr. Daniel J Jackson, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 600 Highland Ave, Csc Box 9988, Madison, WI 53792 Phone: 608-239-3515 | |
Patricia V Staats, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1217 Gilbert Rd, Madison, WI 53711 Phone: 608-274-3636 | |
Michael W Ritter, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 7610 Sawmill Rd, Madison, WI 53717 Phone: 608-831-1528 | |
Dr. Jesse Roach, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-6420 | |
Norris Glick, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 317 Knutson Drive, Madison, WI 53704 Phone: 608-301-1791 |